Major Depressive Disorder Treatment: A Focus on Novel Kappa Opioid Receptor Agents

Major Depressive Disorder Treatment: A Focus on Novel Kappa Opioid Receptor Agents

The goal of this activity is to improve clinicians knowledge of the unmet treatment needs of patients with MDD and their awareness of how investigational agents with novel MOAs, especially those that target residual symptoms, such as anhedonia, may fit into the current treatment paradigm.

  • Provider:Medscape, LLC
  • Activity Link: https://www.medscape.org
  • Start Date: 2025-02-18 06:00:00
  • End Date: 2025-02-18 06:00:00
  • Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
    Nursing: 0.5 hours
    Pharmacy: 0.5 hours
  • Commercial Support: Source: Janssen (Any division) - Amount: 184793.0 - Is Kind Support: False
  • Activity Type: Live Course
  • CME Finder Type: Conference
  • Fee to Participate: No, it's free
  • Measured Outcome: Learner Knowledge, Learner/Team Competence
  • Provider Ship: Directly Provided
  • Registration: Open to all
«
»
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.